Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Varicella Vaccine · 2 trials · 3 indications
The seroresponse rate of VZV antibodies on Day 42 after vaccination among susceptible population.
| Arm | Type | Description |
|---|---|---|
| No vaccination history group | EXPERIMENTAL | Participants aged 1-12 years with no vaccination history of varicella-containing vaccine |
| Vaccination history group | EXPERIMENTAL | Participants aged 2-12 years have received 1 dose of varicella vaccine |
| Varicella vaccine group | EXPERIMENTAL | Participants will receive a single dose of investigational varicella vaccine on Day 0. |
| Varivax | ACTIVE_COMPARATOR | Participants will receive a single dose of Varivax on Day 0. |
| Name | Type | Description |
|---|---|---|
| Varicella Vaccine | BIOLOGICAL | Varicella vaccine manufactured by Sinovac |
| Varivax | BIOLOGICAL | lyophilized powder,subcutaneous injection |
Inclusion Criteria: 1. Healthy children aged 1-12 years; 2. Vaccination history: * Participants aged 1 year old: no vaccination history with any varicella containing vaccine; * Participants aged 2\~12 years old: no vaccination history with any varicella containing vaccine, or have received 1...
Varicella Vaccine is a live vaccine used for the prevention of varicella, commonly known as chickenpox. It is being developed for use in healthy children to provide immunity against the varicella-zoster virus, which causes chickenpox.
Varicella Vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol SVA.
Varicella Vaccine is currently in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. Clinical trials are ongoing to evaluate its immunogenicity and safety in healthy children.
Varicella Vaccine is being studied in two Phase 3 clinical trials. One trial, NCT06314724, has been completed in the Philippines with 642 healthy children aged 12 to 15 months. Another trial, NCT07473427, is planned in Vietnam with 300 healthy children aged 1 year and older.
Varicella Vaccine is a live attenuated vaccine that works by stimulating the immune system to produce a protective response against the varicella-zoster virus. This helps the body develop immunity to chickenpox without causing the full disease.